banter and General Discussion, page-17374

”Big pharmas don’t have the luxury …” - love this opinion of yours.

Barring an easy takeover, what will be a second best option for these behemoths then? Pay up with cold, hard cash and/or access to their infrastructure perhaps? Sounds good and makes a lot of sense to me, especially when quite a few will be going down patent cliffs in the next 3-5 years. The dollars will have to be big though, given how much near and mid-term potential this company’s portfolio of assets holds. It boggles the mind.

Only a matter of time - in short order, dare we say?

DYOR, make up your own mind.